Indium-111-DOTA-Labetuzumab-IRDye800CW
N/A
Report date: 2025/09/12 17:58:35
Base Information
Drug NameIndium-111-DOTA-Labetuzumab-IRDye800CW
Drug Alias NameN/A
Classification +[5]
Mechanisms of Action
Targets
Therapy Area/Indications +[5]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics IncRadboud University Nijmegen
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesRadboud University Medical Center
Active IndicationsN/A
Inactive Indications +[5]
Other Information
ATC CodeN/A
Related LinksN/A